Pharma Watch

Category

Lilly on the Verge of COVID-19 Monoclonal Antibody EUA Approval First for High Risk Patients with Recent Mild-to-Moderate COVID-19 Diagnosis

TrialSite shared that Eli Lilly’s (Lilly) monoclonal antibody program targeting COVID-19 appeared to be working, at least according to some trial site reports. Now Lilly is moving to secure an emergency use authorization for its monotherapy (LY-CoV555) to the U.S....

COVID-19 Vaccine INO-4800 Demonstrates Neutralizing Antibody and T-Cell Immune Responses in Preclinical Models

Inovio Pharmaceuticals (Nasdaq: INO) reported recent preclinical data summaries for their COVID-19 DNA vaccine called INO-4800 demonstrating promising information. Namely, the sponsor’s tests demonstrated robust neutralizing antibody and T cell immune responses...

Ansun Biopharma’s DAS181 Shows Promise in COVID-19 Patients with Respiratory Challenges

Recently, the Wall Street Journal introduced a small, 25-person San Diego-based biotech called Ansun Biophrma (Ansun) reporting on recent success of a drug that cleared COVID-19 symptoms in a small study involving four Chinese patients. With a strong background in...

‘Unprecedented Times call for Bold Moves’ as Competitive Plasma Firms Unite to Battle COVID-19

CSL Behring and Takeda Pharmaceutical Company have initiated an alliance bringing together the world’s leading plasma companies to focus on developing and delivering hyperimmune immunoglobulin to help fight the global war on COVID-19. Led by Australian and American...

Acceleration of First-Patient-First-Visit Study Milestone as Roche Study Investigating Tocilizumab in COVID-19 Pneumonia Patients Enrolls Patients in Spain

Roche recently announce the launch of a global study in collaboration with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to evaluate the safety and efficacy of Actemra/RoActemra (tocilizumab) plus standard of care in hospitalized adult...

Regeneron Leverages its Technology Platform, Process and People in the Hopes of Having A COVID-19 Therapy in Trials by Summer

Regeneron and its “VELOCISUITE®” platform was used to develop a treatment for Ebola (REGN-EB3), currently used by the Congolese government to fight that horrific virus. The New York State-based venture has, like many biopharma companies, dedicated a full force...

Pin It on Pinterest